Repligen (NASDAQ:RGEN) Shares Unloaded Rep. Lisa C. McClain

Posted by Linda Flegge on Nov 26th, 2025

Representative Lisa C. McClain (R-Michigan) recently sold shares of Repligen Corporation (NASDAQ:RGEN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Repligen stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Repligen Trading Down 0.4%

NASDAQ:RGEN traded down $0.62 during trading hours on Wednesday, hitting $171.14. The company had a trading volume of 191,538 shares, compared to its average volume of 822,051. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The company has a market cap of $9.63 billion, a P/E ratio of 8,552.53, a P/E/G ratio of 3.32 and a beta of 1.15. The company has a 50-day moving average of $146.77 and a 200 day moving average of $130.95. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. During the same quarter in the prior year, the firm posted $0.43 earnings per share. Repligen’s quarterly revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 20,000 shares of Repligen stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the sale, the director directly owned 80,743 shares in the company, valued at approximately $12,483,675.23. The trade was a 19.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO James Bylund sold 2,191 shares of Repligen stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the sale, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 49,382 shares of company stock valued at $7,676,802 in the last quarter. Insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGEN. Weiss Ratings reissued a “sell (d+)” rating on shares of Repligen in a research report on Wednesday, November 19th. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, HSBC began coverage on Repligen in a research report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $173.85.

Read Our Latest Research Report on Repligen

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RGEN. Twin Tree Management LP purchased a new position in shares of Repligen in the 1st quarter worth about $29,000. Measured Wealth Private Client Group LLC bought a new stake in Repligen in the third quarter valued at about $29,000. Hantz Financial Services Inc. lifted its stake in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares during the last quarter. Signaturefd LLC raised its holdings in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.